Media release of February 22, 2023

Emerging Markets Healthcare sector comeback

Numerous fundamental factors are indicating that the recent advance by healthcare stocks across the Asia-Pacific region and in emerging market countries is solidifying into a sustained recovery. That applies to Chinese healthcare stocks in particular. The release of pent-up demand in China after zero-COVID restrictions were eased and initial regulatory approvals of innovative Chinese drugs have created promising growth dynamics.

Remo Krauer, Portfolio Manager, Bellevue Asia Pacific Healthcare Fund / Bellevue Emerging Markets Healthcare Fund

After a string of difficult years, a trend reversal is under way in emerging market healthcare stocks. The sector comeback in China is particularly obvious. The upward business momentum of healthcare companies there can be traced to the reopening of the economy after the government abandoned its zero-COVID policy on the one hand and to government reforms to enhance the healthcare systems on the other, which have created new growth triggers.

After all the uncertainty of the past few years, the Chinese healthcare industry can again unleash its full potential. The Chinese healthcare market is forecast to show average annual growth of about 10%. Various subsectors of China’s healthcare industry are profiting from the reopening of the economy. Higher numbers of patients for stationary care have improved clinic capacity utilization. Surgical procedures are one example here. An increase in these procedures is, in turn, boosting business in various subsegments of the medtech industry, for example for manufacturers of prostheses for hip and knee joint replacement procedures in orthopedics, or stent and heart valve providers in cardiology. Sales are also on the rise at distributors and pharmacies, where foot traffic has picked up.

China’s government had no other choice
Healthcare remains a high-priority industry in China. Demand for healthcare products and services is rapidly growing as the country's population rapidly ages, so the government is literally being forced to invest resources in the modernization of existing healthcare structures and in innovative technology. As for government price regulation, the latest signals indicate that price controls are starting to shift in favor of the supply side, which is likely to have a positive impact on company earnings going forward.

To summarize, China offers the most exciting healthcare universe of all emerging market countries today in view of the attractive valuations and high sales and profit growth rates. Chinese companies have clearly improved their innovative capabilities. Biotech companies such as Legend Biotech and BeiGene are now marketing their cancer treatments in the US. BeiGene’s leukemia medicine marketed as Brukinsa belongs to the drug class of BTK inhibitors and has a very good chance of becoming a “best-in-class” BTK inhibitor owing to its superior efficacy. That same applies to Legend Biotech’s cell therapy used to treat multiple myeloma. WuXi Biologics is another company worth noting. It offers R&D and manufacturing services for biologics that are globally competitive.

Breakthrough in Alzheimer’s research
Looking beyond China, there are also companies in other Asian countries that are playing an important role in the development of groundbreaking new drugs. Daiichi Sankyo, a Japanese pharmaceutical company, has partnered with AstraZeneca on Enhertu, a new breast cancer drug launched last year that has peak sales potential in the high-single-digit billions. Eisai Pharma and Biogen were granted marketing authorization for Lecanemab in early January 2023, the first drug that actually slows the progression of Alzheimer’s. In Australia, CSL Ltd received regulatory approval for its hemophilia B gene therapy.

Interesting investment opportunities in India and Brazil
In the Indian healthcare sector, operators of hospital chains such as Apollo Hospitals (digitalization strategy) and generics manufacturers such as Dr. Reddy’s and Sun Pharma (strong positions in India and specialty pharma products in the US) deserve special mention. Outside Asia-Pacific, we see the most attractive investment opportunities in Brazil. We currently like Raia, a pharmacy chain, and Hypera, a company focused on generic and specialty drug manufacturing. Both have little exposure to the economic cycle in Brazil, which gives them a defensive profile. They also stand to reap a considerable benefit from demographic aging and the related above-average healthcare market growth.

China heavily weighted in fund portfolios
We have given Chinese stocks high weightings in the portfolios of both funds. In the Bellevue Emerging Markets Healthcare Fund, the China allocation is more than 60% and in the Bellevue Asia Pacific Healthcare Fund it is about 40%. Generally speaking about half of the Asia Pacific Healthcare Fund’s portfolio is invested in emerging markets and the other half in developed countries in Asia-Pacific, such as Japan, Australia and New Zealand. That gives the fund a somewhat more defensive profile. In the Emerging Markets Healthcare Fund, the China allocation is combined with a higher weighting of Indian stocks and with investments in Brazil, Hungary and the Middle East.

Author: Remo Krauer
Remo Krauer has been a Senior Portfolio Manager Healthcare Funds & Mandates at Bellevue Asset Management since 2018. Previously, he worked at Zürcher Kantonalbank, first as Senior Portfolio Manager, then as Head Portfolio Construction for Private Asset Management. He holds a Bachelors degree in Business Administration from the Zurich University of Applied Sciences.

More information

Bellevue Asia Pacific Healthcare

Bellevue Emerging Markets Healthcare

Contact
Bellevue Asset Management AG, Seestrasse 16 / P.O. Box, CH-8700 Küsnacht/Zurich,
Tanja Chicherio, tel. +41 44 267 67 09, tch@bellevue.ch

www.bellevue.ch

Bellevue – Excellence in Specialty Investments 

Bellevue is a specialized asset manager listed on the SIX Swiss Exchange with core competencies covering healthcare strategies, entrepreneur strategies, alternative and traditional investment strategies. Established in 1993, Bellevue, a House of Investment Ideas staffed by 100 professionals, generates attractive investment returns and creates value added for clients and shareholders alike. Bellevue managed assets of CHF 9.6 bn as at June 30, 2022.

Disclaimer: This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. Liability for the accuracy or completeness of all information in this document is expressly disclaimed. This information does not take into account the specific or future investment objectives, the financial or tax situation or the particular needs of any specific recipient This document does not constitute independent investment research. Interested investors should always seek professional advice before making an investment decision. The information in this document is provided without any guarantees or warranties, for information purposes only, and is intended only for the personal use of the recipient. Every investment involves some risk, especially with regard to of fluctuations in value and return. Investments in foreign currency involve the additional risk that a foreign currency might lose value against an investor's reference currency. This document does not reflect all possible risk factors associated with an investment in the aforementioned securities or financial instruments. Historical performance data and financial market scenarios are no guarantee or indicator of current and future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs adversely affect performance. Financial transactions should only be carried out after thorough study of the current prospectus and are only valid on the basis of/or/and are subject to the terms given in the most recently published prospectus and annual or semi-annual report. Bellevue Funds (Lux) SICAV is admitted for public distribution in Switzerland. Representative in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying Agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zurich. Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: Zeidler Legal Process Outsourcing Ltd., SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Information agent: Zeidler Legal Process Outsourcing Ltd., SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. Bellevue Funds (Lux) SICAV is registered in the CNMV registry of foreign collective investment schemes distributed in Spain, under registration number 938. Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospectus, Key Investor Information Document (“KIID”), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16, CH-8700 Kusnacht. With respect to fund units distributed in or from Switzerland, the place of performance and jurisdiction is established at the registered office of the representative.